PFS analysis. PFS analysis in the ITT population∗ overall (A) and by MRD-negative (10^–5) conversion status by 12 months (B). † Estimated 30-month PFS rates are shown. ∗At a median follow-up of 32.3 months, median PFS was 37.9 months in the D-R group and was not reached in the R group. †MRD-negative by 12 months refers to patients who were MRD-positive at baseline and achieved MRD-negative status (at a threshold of 10^–5) by bone marrow aspirate from randomization to 12 months (+2-month window), but before progressive disease and subsequent antimyeloma therapy. Otherwise, patients were considered MRD-positive. ‡Per study protocol, disease assessments stopped at the end of study treatment (cycle 36), after which patients were only followed for survival. At the time of this analysis, the number of patients who reached the end of study treatment was low, thus resulting in a low number of patients at risk. Two D-R events occurred at the tail end of study assessments: 1 reported at 1134 days (37.26 months) and 1 at 1153 days (37.88 months). Because of these events, there was a sudden and steep drop in the Kaplan-Meier curve for D-R. ITT, intent to treat.